The scope of Sanofi Pasteur’s Research & Development activities is vast and complex, encompassing the entire chain of events before a new vaccine becomes available – from understanding a disease and its biological foundations, to clinical development and testing, to obtaining health authorities’ approval for marketing the new vaccine.
We have currently vaccines in development or submitted for approval to meet the specific needs of different segments of the population (influenza, vaccines combination, etc.) or unmet medical needs (respiratory syncytial virus, etc.).
Published: December 13, 2017
(1) also known as MEDI8897
Respiratory Syncytial Virus
Sanofi Pasteur signed an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, on March 2, 2017, to develop and commercialize a monoclonal antibody--called MEDI8897--for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants.
In addition, Sanofi Pasteur is collaborating with the National Institute of Allergy and Infectious Diseases (NIAID) at the NIH to further advance attenuated RSV candidate vaccines for the prevention of RSV disease in infants and young children.
According to the Centers for Disease Control and Prevention, RSV is the most common cause of lower respiratory tract infections in children younger than 1 year of age in the United States and worldwide*. There are no specific treatments for RSV and there is no vaccine. Current therapies are focused on alleviating the symptoms of the infection.